DouglasMichaelSprouleMD
Child Neurology • New York, NYAssistant Professor of Neurology, Columbia University Medical Center
Dr. Sproule is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
180 Fort Washington Ave
Fl 5
New York, NY 10032Phone+1 212-342-3679
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Child Neurology, 2005 - 2008- New York Presbyterian Hospital (Columbia Campus)Residency, Child Neurology, 2003 - 2006
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 2003 - 2005
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003
Certifications & Licensure
NY State Medical License 2005 - 2027
MA State Medical License 2013 - 2014- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- Clinical Study of Spinal Muscular Atrophy Start of enrollment: 2005 May 01
- Giant Axonal Neuropathy Natural History Study Start of enrollment: 2011 Dec 01
Publications & Presentations
PubMed
- 1322 citationsSingle-Dose Gene-Replacement Therapy for Spinal Muscular AtrophyJerry R. Mendell, Samiah Al-Zaidy, Richard Shell, W. Dave Arnold, Louise R. Rodino-Klapac
The New England Journal of Medicine. 2017-11-01 - 206 citationsOnasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, ...John W. Day, Richard S. Finkel, Claudia A. Chiriboga, Anne M. Connolly, Thomas O. Crawford
The Lancet. Neurology. 2021-04-01 - 122 citationsObservational Study of Spinal Muscular Atrophy Type 2 and 3: Functional Outcomes Over 1 YearPetra Kaufmann, Michael P. McDermott, Basil T. Darras, Richard S. Finkel, Peter B. Kang
Archives of Neurology. 2011-06-13
Press Mentions
- BridgeBio Pharma to Present Preliminary Findings on Its Novel Bioassay Measuring Glycosylated Alpha-Dystroglycan (⍺DG) in Patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)March 17th, 2023
- BridgeBio Pharma (BBIO) Reports 12-Month Results from Phase 2 Study of BBP-418October 14th, 2022
Dosing Begins in Phase 2 Trial Testing Oral Therapy BBP-418 for LGMD2iMarch 2nd, 2021- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
